Clinical Trials

I2B has recognized expertise in the design and management of clinical trials (phase I - IV) in inflammatory and autoimmune diseases. This comprises several medical fields including internal medecine, rheumatology, gastroenterology, nephrology, pulmonology, ophthalmology and neurology.

WP3

UVEREG

​Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose​
Uveitis is a leading cause of blindness in the children and young adult's populations. One third of etiology are idiopathic. The ...
WP3

GEMRITUX

Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
The Membranous Nephropathy is one of the most common cause of Nephrotic Syndrome of adults. In 2/3 of patients the cause of the disease is idiopathic. This can also b...
WP3

Impact Crohn

Impact of the Fecal Flora Transplantation on Crohn's DiseaseCrohn's disease is a chronic and relapsing inflammatory bowel disease. Many data show that the intestinal flora is involved in the disease and it has been show t...
WP3

MSIL2

Biological activity and safety of low dose IL2 in Relapsing Remitting Multiple Sclerosis​
Interleukin‐2 (IL‐2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising...
DHU:i2B

QUO VADIS

​A prospective observational study to evaluate the relationship between disease state and change in quality of life in Ankylosing Spondylitis patients treated with Remicade (infliximab) or S...
DHU:i2B

SPACING

Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or infliximab), and in stable low disease activity for at...
DHU:i2B

Transimmunom

Phenomics in Autoimmune and Inflammatory Diseases​​
The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammator...
WP3

DFIL2

Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes​ 
IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to control the autoimmune destruction of beta-cells in patients with Type 1 D...
WP3

DIABIL2

European phase-II clinical trial evaluating efficacy of low dose rhIL-2 in patients with recently-diagnosed type 1 diabetes
Clinical and preclinical studies, together with supportive mechanistic da...
DHU:i2B

Phase IV Study CL3-12911-040

​Long-term follow-up of patients from CL3-12911-018 study (5 year knee prosthesis in patients with​​ knee osteoarthritis​)  
Sponsor: Pfizer
DHU:i2B

Rheumatoid Arthritis

A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis.
​An exploratory clinical study to investigate mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumato...
WP3

TRANSREG

​TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological and clinical responses to the administration of low dose of IL-2 across 11 selected pathologies (12 patients/pathology): rheumatoid arthritis, ankylosing spondyliti...